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Abstract Tofacitinib is an oral Janus kinase inhibitor for the
treatment of rheumatoid arthritis (RA). To characterise the
relative safety profile of tofacitinib to biologic disease-
modifying antirheumatic drugs (bDMARDs), the accrued
patient-years (pt-yrs) of exposure needed in an RA clinical
trial programme to detect a potential increase in risk of spe-
cific adverse events (AEs) was determined. This case study/
framework was constructed on the pt-yrs’ accrual within
pooled phase (P)1, P2 and P3, as well as long-term extension,
studies of tofacitinib in RA (March 2015 data-cut) and pub-
lished AE incidence rates for bDMARDs. Sample size calcu-
lations were based on a Poisson distribution to estimate pt-yrs’
exposure required for 90% probability that the lower bound of
the 95 % confidence interval for tofacitinib/bDMARD would
be >1, assuming that tofacitinib rates were 1.2×/1.5×/2.0×
greater than comparator rates. AE rates for bDMARDs were
derived from sources intended to optimise similarity with the
tofacitinib database in terms of baseline characteristics, study
duration and follow-up. Based on the tofacitinib exposure
accrued (19,406 pt-yrs), data were sufficient (90 %
probability) to detect potential differences over external
bDMARD comparator rates in serious infections (≥1.2×), ma-
lignancies (excluding non-melanoma skin cancer [NMSC]),
NMSC, major adverse cardiovascular events (MACE) and
lymphoma (each ≥1.5×), as well as opportunistic infections
and gastrointestinal perforations (≥2×), should they exist. This
risk characterisation approach can support the comparative
safety of new RA medications. To date, tofacitinib safety ap-
pears similar to approved published data from bDMARDs
with respect to serious infections, malignancies (excluding
NMSC), NMSC, MACE, lymphoma, opportunistic infections
and gastrointestinal perforations.
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Introduction
Safety data collected during the development of new rheuma-
toid arthritis (RA) therapies are generally derived from
randomised controlled trials (RCTs) and long-term extension
(LTE) studies. Individual RCTs typically include small patient
numbers and limited treatment periods [1, 2]. Control treat-
ment duration may limit the exposure available to derive rel-
ative safety measures with concurrent internal controls, par-
ticularly for events of low frequency or long latency. Although
LTE studies are conducted over longer treatment periods,
many of these typically do not include a comparator arm, are
open-label and may lack generalisability due to possible se-
lection biases [2]; such factors complicate comparisons with
controls.
Tofacitinib is an oral Janus kinase inhibitor for the treat-
ment of RA. Tofacitinib clinical efficacy and safety have been
demonstrated in phase (P)3 and LTE studies (Supplementary
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Material) [3–9], including comparisons with methotrexate [6]
and adalimumab [8], and safety data up to 96 months [10];
however, active-control trials with biologic disease-modifying
antirheumatic drugs (bDMARDs) are only available up to
12 months, and there is limited precision for rare events.
To further characterise tofacitinib safety, analyses were
conducted to understand how the totality of accrued patient-
years (pt-yrs) of tofacitinib exposure from clinical trials could
inform evaluations of safety events, expanding on recently
published methodology [1, 11]. These analyses were designed
to estimate the exposure needed to provide 90 % probability
that the lower bound of the 95 % confidence interval (CI) of
selected safety events for tofacitinib was greater than external
bDMARD comparator rates. The methodology used here was
not intended to provide a comprehensive overview of all pos-
sible safety outcomes, but rather to be an exemplar for a gen-
eralised approach of safety contextualisation of data collected
during a clinical trial programme versus other therapies.
Materials and methods
External comparator populations
For this analysis, the Curtis et al. methodology was applied
[1]. bDMARDs were chosen for comparison with tofacitinib,
and incidence rates (IRs) for AEs of interest in patients with
moderate to severe RA were obtained to determine the
tofacitinib exposure needed to detect a potential increased risk
of the following AEs: serious infection events (SIEs), all ma-
lignancies (excluding non-melanoma skin cancer [NMSC]),
NMSC, major adverse cardiovascular events (MACE), oppor-
tunistic infections (OIs), lymphoma and gastrointestinal (GI)
perforations. These AEs were selected by the study team as
important potential or identified risks for RA patients that
were both clinically relevant and feasible for study under the
methodological framework. For instance, although pregnancy
safety outcomes were of interest, there were no adequately
powered, well-controlled studies of pregnant women treated
with tofacitinib. For the outcomes of interest, data from mul-
tiple sources (e.g. observational studies, RCTs, meta-analyses)
were used and data sources were focussed on defining and
optimising comparability with the tofacitinib clinical trial pro-
gramme (Table 1; Supplementary Material).
Tofacitinib clinical trial population
The tofacitinib clinical trial RA population included patients
from two P1 studies, nine P2 RCTs, six P3 RCTs and two
open-label LTE studies (Supplementary Material). One LTE
study was ongoing at the time of analysis (March 2015 data-
cut; unlocked).
Analysis
Background rates of AEs were derived from external
bDMARD comparator populations, as described previously.
IRs were expressed as the number of unique patients with
events per 100 pt-yrs’ exposure, assuming a constant hazard
over time. Sample size calculations were based on a Poisson
distribution to estimate the minimum pt-yrs’ exposure needed
to have 90% power to detect that the lower bound of the CI of
tofacitinib/bDMARD would be >1, assuming that the true
tofacitinib IRs were 1.2×, 1.5× or 2.0× greater than
bDMARD IRs; multiplier thresholds were based on clinical
relevance and 1.5× was used by Curtis et al., as agreed upon
with the FDA for characterising tocilizumab safety [1].
Accrued exposure data collected during tofacitinib studies
(P123LTE) were pooled for analysis. The number of pt-yrs’
exposure within the pooled dataset was compared with the
calculated minimum tofacitinib exposure to detect a 1.2×,
1.5× or 2.0× increase in risk over external bDMARD compar-
ator populations for each AE.
Results
As of March 2015, 19,406 pt-yrs’ tofacitinib exposures (all
doses) were accrued from 6194 patients across the P123LTE
database. IRs for AEs of interest in the external bDMARD
comparator populations, with similar characteristics to pa-
tients enrolled in the tofacitinib clinical trial programme, are
shown in Table 1. A nomogramwas developed to estimate the
number of pt-yrs’ tofacitinib exposure required to detect in-
creases in AEs of various frequencies (Fig. 1).
Based on 19,406 pt-yrs’ tofacitinib exposure, sufficient da-
ta were available to detect potential increases over estimated
background bDMARD IRs in SIEs (≥1.2×), malignancies (ex-
cluding NMSC), NMSC, MACE and lymphoma (each ≥1.5),
should they exist. Given the rarity of OIs and GI perforations
reported in RA populations, the accrued pt-yrs’ exposure al-
lows for the detection of a potential two-fold increase with
tofacitinib relative to bDMARD IRs.
Discussion
A robust clinical trial safety database is important for the
risk/benefit assessment of a new molecular entity (NME)
and should meet regulator recommendations on the extent of
population exposure to assess clinical safety [19]. At the time
of initial registration, RA clinical trials predominantly fo-
cussed on comparisons with placebo, with pooling across tri-
als to achieve the necessary extent of exposure. However, as
the number of effective RA therapies has increased and ethical
considerations have further limited the length of placebo
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exposure in contemporary clinical trial programmes, interest
has shifted to characterising the safety profile of new medica-
tions versus other active medications rather than placebo.
Modern development programmes generally include head-
to-head or active comparator trials, with the primary intent of
benchmarking the efficacy of NME. While the duration of
active comparator trials is typically longer compared with
placebo-controlled trials and is not as restrictive in terms of
duration of exposure, logistical considerations, including sam-
ple size, study duration and event frequency, continue to limit
the ability to draw precise comparisons for events with low
frequency or long latency.
Furthermore, the challenge remains as to how to determine
a priori how much data constitutes a sufficiently large safety
database in such a clinical trial programme. Due to these dif-
ficulties, there is utility in alternative methods to compare the
evidence of safety events between active therapies. Our ap-
proach, which focussed on confirmation that the minimum
drug exposure within the tofacitinib clinical trial programme
has been achieved to confidently ascertain whether AE rates
are higher than other available therapies, may improve the
utility of other clinical trial programme databases.
The data suggest that tofacitinib exposure from the clinical
programme is sufficient to detect possible risk differences
Table 1 Pt-yrs’ exposure to tofacitinib required for the lower bound of 95 % CI to exceed background rate in external bDMARD comparator
populations assuming an increase in observed rate of 1.2×, 1.5× or 2.0×
Event External bDMARD comparator population IR reported for external
bDMARD comparator
population per 100 pt-yrsa
Follow-up exposure (pt-yrs)
to tofacitinib required to
detect an assumed increased
risk relative to bDMARDs
with 90 % powerb
1.2× 1.5× 2.0×
SIE Systematic review/clinical trial meta-analysis [12] Point estimate 4.90 6151 1076 311
Lower 95 % CI 4.41 6568 1230 348




Clinical trials meta-analysis (Pfizer Inc 2015, data on file) Point estimate 0.95 30,945 5704 1699
Lower 95 % CI 0.79 38,165 6872 2004
Upper 95 % CI 1.14 25,734 4743 1413
NMSC Published systematic review/meta-analysis of malignancies from
observational studies/clinical trials [13]
0.35 84,544 15,241 4349
Observational studies literature review (Pfizer Inc 2015, data on file) Low 0.21 137,762 25,444 7263
High 1.34 22,366 3933 1146
MACE Corrona TNFi cohort (Pfizer Inc 2013, data on file) 0.54 54,684 10,084 2942
OI Based on published long-term follow-up data of patients with active RA
treated with adalimumab [14]; published literature review of infections
and bDMARD therapy among patients with RA [15]
0.25c 118,491 21,363 6098
Lymphoma Observational studies literature review (Pfizer Inc 2015, data on file) Low 0.019 1,562,987 281,872 80,494
High 0.34 87,040 15,691 4478
GI perforation Published claims database analysis [16, 17] 0.13 228,162 39,228 11,746
Lower 95 % CI 0.08 370,964 66,896 19,101
Upper 95 % CI 0.19 156,011 28,129 8030
Published RABBIT registry datad [18] High 0.066 449,723 77,326 22,080
Observational studies literature review (Pfizer Inc 2015, data on file) Low 0.05 593,737 107,072 30,575
High 0.19 156,011 28,129 8030
Shaded cells highlight events that have accrued the needed tofacitinib exposure for the detection of respective 1.2×, 1.5× or 2.0×-fold increased risk,
should they occur, based upon trial data current through March 2015
bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, Corrona Consortium of Rheumatology Researchers of North
America, EU European, GI gastrointestinal, IR incidence rate, MACE major adverse cardiovascular event, ND not determined, NMSC non-melanoma
skin cancer, OI opportunistic infection, pt-yrs patient years, RA rheumatoid arthritis, RABBIT Rheumatoid Arthritis Observational Biological Therapy
Register, SIE serious infection event, TNFi tumour necrosis factor inhibitor
a Low and high refer to the lowest and highest IR values, respectively, from a range of reported values
b The estimated tofacitinib exposure by April 2015 within the RA clinical programme is 19,406 pt-yrs
c No CI available
d The low value was 0 (golimumab data); therefore, exposure data could not be calculated
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from bDMARDs of ≥1.2–1.5× for several AEs of interest;
however, for OIs and GI perforations, only risk differences
of ≥2× could be detected due to the lower frequency of these
events within the available data sources. This reflects the in-
herent limitation of event frequency in precisely comparing
such events. For such rare events, the potential risk differences
that can be detected using this method may be considered
insufficient to fully inform risk/benefit assessments. This lim-
itation highlights the important role of observational studies,
conducted in larger and more diverse patient populations, to
assess the relative frequency of such events and those with
long latency periods. Such characterisation can be achieved
through prospective active surveillance within register frame-
works and routine pharmacovigilance surveillance within the
clinical practice setting. Ideally, one could potentially pool
clinical trial data, continued by real-world observation, to pro-
vide maximal person-time follow-up.
In this analysis, limitations were introduced from the data
sources used. The paucity of data available from clinical trials
for some AEs of interest required the use of observational data
sources and meta-analyses to provide the necessary IRs for
these events in cohorts of patients receiving bDMARDs.
The addition of observational sources, rather than only clinical
trial data, increased the breadth of IRs available and may have
influenced the sensitivity to detect a potential increased risk
with tofacitinib relative to bDMARDs. These data, while valu-
able, introduce a wider range of patient characteristics and risk
factors representative of clinical practice versus trial-specific
inclusion/exclusion criteria, as well as heterogeneity in case
definitions and the methods of outcome ascertainment.To ad-
dress these limitations, where possible, bDMARD popula-
tions were selected to optimise similarity of comparisons with
the tofacitinib clinical trial database and provide a conserva-
tive range of IRs.
A similar analytic approach was used for tocilizumab for
regulatory purposes, where the number of tocilizumab-
exposed pt-yrs needed to detect a ≥50 % increase in risk for
key safety events versus a bDMARD population (90 % pow-
er) was determined. The overall methodologies were similar,
except that within this case example, additional efforts to ‘har-
monise’ the comparator patient populations were made, and
all tofacitinib-related person-time was accrued within the clin-
ical trial setting versus the combination of clinical trial and
person-time estimates based on post-marketing exposure for
tocilizumab [1].
The methodology described here for the tofacitinib clinical
trial programme provides clinicians and experts in
pharmacovigilance with an alternative way to gain perspective
on the pt-yrs’ exposure required to evaluate differences in
safety events of interest relative to comparator therapies. The
AEs selected for this analysis were those identified by the
study team as the most clinically relevant potential risks for
RA patients. However, the methodology described herein
could be applied to evaluate the relative risk of other safety
outcomes of interest, such as abnormal laboratory test results
associated with clinically relevant outcomes, which have been
reported elsewhere in tofacitinib-treated RA patients [20, 21].
This approach could support the assessment of comparative
safety outcomes for new RA medications. Based on our
dataset, a nomogram was developed to estimate the number
of pt-yrs’ tofacitinib exposure required to detect potential in-
creases in risk versus bDMARDs, as a tool that could be more
broadly applied in the design of long-term safety clinical trials























































Fig. 1 Nomogram showing the minimum amount of tofacitinib exposure
(pt-yrs) required to detect a significant difference of 1.5× and 2.0× versus
a bDMARD comparator in relation to example background event rates.
a As of March 2015. IRs for AEs of interest are based on estimated values
from the data presented in Table 1. AE adverse event, bDMARD biologic
disease-modifying antirheumatic drug, GI gastrointestinal, IR incidence
rate, MACE major adverse cardiovascular event, NMSC non-melanoma
skin cancer, pt-yrs patient-years, OI opportunistic infection, SIE serious
infection event
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exposure calculations was selected to ensure a higher chance
of detecting potential differences rather than a lower threshold.
Consequently, the tofacitinib exposure calculated represents a
conservative estimate of the total pt-yrs follow-up.
Although our case study used a superiority hypothesis for
safety events, non-inferiority testing would result in similar
exposure sample size cutoffs for each AE of interest within
non-inferiority margin set at the same values, as described for
each event within the nomogram (1.5×, 2.0×). In non-
inferiority testing, if the upper bound of 95 % CI based on
the observed tofacitinib rate was <1.5× and 2.0× of bDMARD
comparator rates, then 1.5× and 2.0× risks could be excluded.
Therefore, regardless of superiority test (to detect assumed
difference) or non-inferiority test (to exclude certain differ-
ence), similar inference could be drawn; an assumption of
the analysis was that the IR of AEs for bDMARDs were con-
stant over time. Whether this is a valid assumption can be
tested as accumulating data allows.
The tofacitinib data are derived entirely from clinical
trial data sources. Given that >55,000 patients worldwide
have received tofacitinib as of May 2015 (data on file), in
post-marketing experience, additional perspective for the
evaluation of rare events in this more heterogeneous real-
world patient and prospective active surveillance using
registries is ongoing to fully define the risks associated
with therapy. Future safety analyses might also include
alternative comparator therapies within such registries,
which would complement both the comparative clinical
trials and the methods described here. Comparative safety
outcome trials (NCT02092467/A3921133) are underway,
but data will not be available in the near future. The cre-
ation of a safety data repository of blinded patient-level
data to permit cross-comparison between existing thera-
pies and new medications could allow for standardisation
of cohort and outcome definitions and better comparabil-
ity for key subgroups. This approach has been preliminar-
ily successful in trying to harmonise international compar-
isons between observational RA registries [22, 23].
Additionally, a Bayesian approach, incorporating the lat-
est safety estimates, could be considered. The current es-
timated sample size ignores the event rates associated
with tofacitinib; this analytic framework is suitable for
planning how much exposure data might be needed before
actual tofacitinib rates are available.
To conclude, our risk characterisation approach represents
an indirect method to contextualise the safety profile of newly
introduced RA medications versus established therapies, and
provides clinicians and regulatory authorities with relevant
context to inform labelling and treatment choices for RA pa-
tients. To date, the safety of tofacitinib appears similar to ap-
proved published data from bDMARDs with respect to SIEs,
all malignancies (excluding NMSC), NMSC, MACE, OIs,
lymphoma and GI perforations.
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